Dostarlimab for the treatment of advanced endometrial cancer
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2022.2044791
Abstract: ABSTRACT Introduction Between 20% and 30% of the endometrial cancers (EC) are associated with a deficiency of a mismatch repair (MMRd) protein or high microsatellite instability (MSI-H), characteristics that render the tumor more sensitive to… read more here.
Keywords: dostarlimab; platinum containing; treatment advanced; containing regimen ... See more keywords